Discovery of cell-permeable inhibitors for human succinyl-CoA:glutarate-CoA transferase
Glutaric Aciduria Type I (GA-1) is a recessive, serious neurometabolic disorder characterized by a build-up of toxic metabolites in the lysine metabolic pathway with no current pharmacological treatment. Previous mouse studies have shown that a deficiency in SUGCT attenuates the accumulation of some of these metabolites in vivo. These results highlight the potential for SUGCT as a therapeutic target in treating GA-1. We had previously identified biochemical inhibitors for SUGCT and had solved the crystal structure of the protein, both apo and bound to an inhibitor. However, we were unable to demonstrate cellular activity for these compounds. In this study, we report findings from additional in vitro high-throughput screening and address these challenges by developing an improved cell-based assay to detect SUGCT inhibition. We show that by improving the permeability of valsartan using its ethyl ester prodrug, SUGCT is effectively inhibited in GA-1 cells. We also identify meclofenamic acid as a new SUGCT inhibitor with cellular activity, providing additional validation and highlighting this enzyme target potential for GA-1.